Finasteride and Zinc
Supplement–drug interaction evidence from the TruthStack database.
| Severity | LOW |
|---|---|
| Evidence Tier | Limited |
| Interaction Type | PHARMACODYNAMIC RISK |
| Mechanism | PHARMACODYNAMIC |
| Last Reviewed | 2026-02-24 |
Summary
Zinc has demonstrated 5-alpha-reductase inhibitory activity in vitro. Combined with finasteride, theoretical additive DHT reduction possible though clinical significance unclear.
CYP Enzyme Profiles
Published CYP enzyme data for compounds in this interaction:
Finasteride: CYP3A4 substrate (moderate)
Shared Pharmacodynamic Endpoints
Both compounds influence the same physiological endpoints in the same direction:
| Endpoint | Direction | Finasteride | Zinc |
|---|---|---|---|
| DHT | DECREASE | STRONG | WEAK |
Cumulative effect on shared endpoints may exceed individual compound profiles. This is relevant to discussion with a prescribing clinician.
What We Don't Know
This interaction has limited evidence. Key gaps may include: direct clinical trial data for this specific combination, dose-response relationships, and long-term outcome data. Absence of evidence is not evidence of absence.
API Reference
Open, unauthenticated. Returns JSON. Developer documentation
Sources
Primary: 21806658